T-lymphocyte interaction with stromal, bone and hematopoietic cells in the bone marrow

Immunology and Cell Biology

Volumn 87, Issue 1, 2009, Pages 20-29

  Di Rosa, Francesca ^a,b  

^a CNR   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Bone; Bone marrow; Hematopoiesis; Immunological memory; Mesenchymal stromal cells; T lymphocytes

Indexed keywords

INTERLEUKIN 15; INTERLEUKIN 7; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BONE MARROW CELL; BONE METABOLISM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; HEMATOPOIESIS; HEMATOPOIETIC CELL; HOMEOSTASIS; HUMAN; IMMUNITY; MEMORY T LYMPHOCYTE; MICROENVIRONMENT; OSTEOPOROSIS; REVIEW; STROMA CELL; T LYMPHOCYTE;

ANIMALS; BONE AND BONES; BONE MARROW; CELL COMMUNICATION; CELL MOVEMENT; CYTOKINES; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HUMANS; STROMAL CELLS; T-LYMPHOCYTE SUBSETS;

EID: 58149402216     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2008.84     Document Type: Review

References (130)

1. Pabst R, Binns RM, Westermann J. What is the function of peripheral lymphocytes migrating to the thymus and of B lymphocytes proliferating in the thymus? Thymus 1989; 13: 149-156.
2. Agus DB, Surh CD, Sprent J. Reentry of T cells to the adult thymus is restricted to activated T cells. J Exp Med 1991; 173: 1039-1046.
3. Westermann J, Smith T, Peters U, Tschernig T, Pabst R, Steinhoff G et al. Both activated and nonactivated leukocytes from the periphery continuously enter the thymic medulla of adult rats: phenotypes, sources and magnitude of traffic. Eur J Immunol 1996; 26: 1866-1874.
4. Sprent J, Surh CD. Re-entry of mature T cells to the thymus: an epiphenomenon? Immunol Cell Biol 2009; 87: 46-49.
5. Hale JS, Fink PJ. Back to the thymus: peripheral T cells come home. Immunol Cell Biol 2009; 87: 58-64.
6. Di Rosa F, Pabst R. The bone marrow: a nest for migratory memory T cells. Trends Immunol 2005; 26: 360-366.
7. Di Rosa F, Santoni A. Bone marrow CD8 T cells are in a different activation state than those in lymphoid periphery. Eur J Immunol 2002; 32: 1873-1880.
8. Parretta E, Cassese G, Barba P, Santoni A, Guardiola J, Di Rosa F. CD8 cell division maintaining cytotoxic memory occurs predominantly in the bone marrow. J Immunol 2005; 174: 7654-7664.
9. Cassese G, Parretta E, Pisapia L, Santoni A, Guardiola J, Di Rosa F. Bone marrow CD8 cells down-modulate membrane IL-7R{alpha} expression and exhibit increased STAT-5 and p38 MAPK phosphorylation in the organ environment. Blood 2007; 110: 1960-1969.
10. Parretta E, Cassese G, Santoni A, Guardiola J, Vecchio A, Di Rosa F. Kinetics of in vivo proliferation and death of memory and naive CD8 T cells: parameter estimation based on 5-bromo-2′-deoxyuridine incorporation in spleen, lymph nodes, and bone marrow. J Immunol 2008; 180: 7230-7239.
11. Feuerer M, Beckhove P, Garbi N, Mahnke Y, Limmer A, Hommel M et al. Bone marrow as a priming site for T-cell responses to blood-borne antigen. Nat Med 2003; 9: 1151-1157.
12. Mazo IB, Honczarenko M, Leung H, Cavanagh LL, Bonasio R, Weninger W et al. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity 2005; 22: 259-270.
13. Becker TC, Coley SM, Wherry EJ, Ahmed R. Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells. J Immunol 2005; 174: 1269-1273.
14. Paiardini M, Cervasi B, Engram JC, Gordon SN, Klatt NR, Muthukumar A et al. Bone marrow-based homeostatic proliferation of mature T-cells in non-human primates: implications for AIDS pathogenesis. Blood 2008, e-pub ahead of print.
15. Benner R, Meima F, van der Meulen GM. Antibody formation in mouse bone marrow. II. Evidence for a memory-dependent phenomenon. Cell Immunol 1974; 13: 95-106.
16. Slifka MK, Antia R, Whitmire JK, Ahmed R. Humoral immunity due to long-lived plasma cells. Immunity 1998; 8: 363-372.
17. McHeyzer-Williams LJ, McHeyzer-Williams MG. Antigen-specific memory B cell development. Annu Rev Immunol 2005; 23: 487-513.
18. Ueda Y, Kondo M, Kelsoe G. Inflammation and the reciprocal production of granulocytes and lymphocytes in bone marrow. J Exp Med 2005; 201: 1771-1780.
19. Walsh MC, Kim N, Kadono Y, Rho J, Lee SY, Lorenzo J et al. Osteoimmunology: interplay between the immune system and bone metabolism. Annu Rev Immunol 2006; 24: 33-63.
20. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71-74.
21. Monteiro JP, Benjamin A, Costa ES, Barcinski MA, Bonomo A. Normal hematopoiesis is maintained by activated bone marrow CD4+ T cells. Blood 2005; 105: 1484-1491.
22. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 2005; 22: 285-294.
23. Li Y, Toraldo G, Li A, Yang X, Zhang H, Qian WP et al. B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. Blood 2007; 109: 3839-3848.
24. Di Rosa F, Santoni A. Memory T-cell competition for bone marrow seeding. Immunology 2003; 108: 296-304.
25. Ponomaryov T, Peled A, Petit I, Taichman RS, Habler L, Sandbank J et al. Induction of the chemokine stromal-derived factor-1 following DNA damage improves human stem cell function. J Clin Invest 2000; 106: 1331-1339.
26. Sipkins DA, Wei X, Wu JW, Runnels JM, Cote D, Means TK et al. In vivo imaging of specialized bone marrow endothelial microdomains for tumour engraftment. Nature 2005; 435: 969-973.
27. + human memory T cells. J Immunol 2000; 165: 716-724.
28. Cinamon G, Shinder V, Alon R. Shear forces promote lymphocyte migration across vascular endothelium bearing apical chemokines. Nat Immunol 2001; 2: 515-522.
29. + memory T cells. Cancer Res 2003; 63: 5582-5586.
30. + T cells with potent recall function. J Immunol 2006; 177: 6730-6737.
31. + T cells with unique homing phenotype within the human bone marrow. Blood 2008; 112: 3293-3302.
32. Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H. Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 2008; 112: 1078-1084.
33. Sebzda E, Zou Z, Lee JS, Wang T, Kahn ML. Transcription factor KLF2 regulates the migration of naive T cells by restricting chemokine receptor expression patterns. Nat Immunol 2008; 9: 292-300.
34. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004; 22: 745-763.
35. Letsch A, Knoedler M, Na IK, Kern F, Asemissen AM, Keilholz U et al. CMV-specific central memory T cells reside in bone marrow. Eur J Immunol 2007; 37: 3063-3068.
36. + T cells specific for current and historical viral antigens: a study in patients with benign hematological disorders. J Immunol 2007; 179: 5387-5398.
37. Pabst R, Kaatz M, Westermann J. In situ labelling of bone marrow lymphocytes with fluorescein isothiocyanate for lymphocyte migration studies in pigs. Scand J Haematol 1983; 31: 267-274.
38. Pabst R, Miyasaka M, Dudler L. Numbers and phenotype of lymphocytes emigrating from sheep bone marrow after in situ labelling with fluorescein isothiocyanate. Immunology 1986; 59: 217-222.
39. + regulatory T cells that traffic through CXCL12/CXCR4 signals. Cancer Res 2004; 64: 8451-8455.
40. Halin C, Scimone ML, Bonasio R, Gauguet JM, Mempel TR, Quackenbush E et al. The S1P-analog FTY720 differentially modulates T-cell homing via HEV: T-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. Blood 2005; 106: 1314-1322.
41. Taylor PA, Ehrhardt MJ, Lees CJ, Tolar J, Weigel BJ, Panoskaltsis-Mortari A et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood 2007; 110: 3480-3488.
42. Klonowski KD, Williams KJ, Marzo AL, Blair DA, Lingenheld EG, Lefrancois L. Dynamics of blood-borne CD8 memory T cell migration in vivo. Immunity 2004; 20: 551-562.
43. + T cells may be a pathogenic reservoir for chronic colitis. Gastroenterology 2007; 132: 176-189.
44. Tomita T, Kanai T, Nemoto Y, Fujii T, Nozaki K, Okamoto R et al. Colitogenic CD4(+) effector-memory T cells actively recirculate in chronic colitic mice. Inflamm Bowel Dis 2008, e-pub ahead of print.
45. +TCR- cells in whole bone marrow facilitate the engraftment of hematopoietic stem cells across allogeneic barriers. Immunity 1999; 11: 579-590.
46. Tripp RA, Topham DJ, Watson SR, Doherty PC. Bone marrow can function as a lymphoid organ during a primary immune response under conditions of disrupted lymphocyte trafficking. J Immunol 1997; 158: 3716-3720.
47. Bonasio R, von Andrian UH. Generation, migration and function of circulating dendritic cells. Curr Opin Immunol 2006; 18: 503-511.
48. Cavanagh LL, Bonasio R, Mazo IB, Halin C, Cheng G, van der Velden AW et al. Activation of bone marrow-resident memory T cells by circulating, antigen-bearing dendritic cells. Nat Immunol 2005; 6: 1029-1037.
49. Jahn B, Bergmann L, Weidmann E, Brieger J, Fenchel K, Schwulera U et al. Bone marrow-derived T-cell clones obtained from untreated acute myelocytic leukemia exhibit blast directed autologous cytotoxicity. Leuk Res 1995; 19: 73-82.
50. Noonan K, Matsui W, Serafini P, Carbley R, Tan G, Khalili J et al. Activated marrow-infiltrating lymphocytes effectively target plasma cells and their clonogenic precursors. Cancer Res 2005; 65: 2026-2034.
51. Beckhove P, Feuerer M, Dolenc M, Schuetz F, Choi C, Sommerfeldt N et al. Specifically activated memory T cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest 2004; 114: 67-76.
52. Schmitz-Winnenthal FH, Volk C, Z'graggen K, Galindo L, Nummer D, Ziouta Y et al. High frequencies of functional tumor-reactive T cells in bone marrow and blood of pancreatic cancer patients. Cancer Res 2005; 65: 10079-10087.
53. Muller-Berghaus J, Ehlert K, Ugurel S, Umansky V, Bucur M, Schirrmacher V et al. Melanoma-reactive T cells in the bone marrow of melanoma patients: association with disease stage and disease duration. Cancer Res 2006; 66: 5997-6001.
54. Olsson B, Andersson PO, Jernas M, Jacobsson S, Carlsson B, Carlsson LM et al. T-cell-mediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med 2003; 9: 1123-1124.
55. Feuerer M, Beckhove P, Bai L, Solomayer EF, Bastert G, Diel IJ et al. Therapy of human tumors in NOD/SCID mice with patient-derived reactivated memory T cells from bone marrow. Nat Med 2001; 7: 452-458.
56. Slifka MK, Whitmire JK, Ahmed R. Bone marrow contains virus-specific cytotoxic T lymphocytes. Blood 1997; 90: 2103-2108.
57. Sato K, Suematsu A, Okamoto K, Yamaguchi A, Morishita Y, Kadono Y et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006; 203: 2673-2682.
58. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci USA 2004; 101: 16004-16009.
59. Tough DF, Sprent J. Turnover of naive- and memory-phenotype T cells. J Exp Med 1994; 179: 1127-1135.
60. Welsh RM, Selin LK. No one is naive: the significance of heterologous T-cell immunity. Nat Rev Immunol 2002; 2: 417-426.
61. Tough DF, Borrow P, Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996; 272: 1947-1950.
62. Sapoznikov A, Pewzner-Jung Y, Kalchenko V, Krauthgamer R, Shachar I, Jung S. Perivascular clusters of dendritic cells provide critical survival signals to B cells in bone marrow niches. Nat Immunol 2008; 9: 388-395.
63. Sitkovsky M, Lukashev D. Regulation of immune cells by local-tissue oxygen tension: HIF1 alpha and adenosine receptors. Nat Rev Immunol 2005; 5: 712-721.
64. Pulle G, Vidric M, Watts TH. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival. J Immunol 2006; 176: 2739-2748.
65. Sabbagh L, Snell LM, Watts TH. TNF family ligands define niches for T cell memory. Trends Immunol 2007; 28: 333-339.
66. Wilson A, Trumpp A. Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol 2006; 6: 93-106.
67. Minges Wols HA, Underhill GH, Kansas GS, Witte PL. The role of bone marrow-derived stromal cells in the maintenance of plasma cell longevity. J Immunol 2002; 169: 4213-4221.
68. Cassese G, Arce S, Hauser AE, Lehnert K, Moewes B, Mostarac M et al. Plasma cell survival is mediated by synergistic effects of cytokines and adhesion-dependent signals. J Immunol 2003; 171: 1684-1690.
69. Ma A, Koka R, Burkett P. Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006; 24: 657-679.
70. Rochman I, Paul WE, Ben-Sasson SZ. IL-6 increases primed cell expansion and survival. J Immunol 2005; 174: 4761-4767.
71. + T cells. J Immunol 2007; 178: 778-787.
72. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P et al. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002; 99: 3838-3843.
73. Schaffler A, Scholmerich J, Salzberger B. Adipose tissue as an immunological organ: Toll-like receptors, C1q/TNFs and CTRPs. Trends Immunol 2007; 28: 393-399.
74. Menu E, Asosingh K, Van Riet I, Croucher P, Van Camp B, Vanderkerken K. Myeloma cells (5TMM) and their interactions with the marrow microenvironment. Blood Cells Mol Dis 2004; 33: 111-119.
75. Tokoyoda K, Egawa T, Sugiyama T, Choi BI, Nagasawa T. Cellular niches controlling B lymphocyte behavior within bone marrow during development. Immunity 2004; 20: 707-718.
76. Huang W, La Russa V, Alzoubi A, Schwarzenberger P. Interleukin-17A: a T-cell-derived growth factor for murine and human mesenchymal stem cells. Stem Cells 2006; 24: 1512-1518.
77. Miyake T, Inaba M, Fukui J, Ueda Y, Hosaka N, Kamiyama Y et al. Prevention of graft-versus-host disease by intrabone marrow injection of donor T cells: involvement of bone marrow stromal cells. Clin Exp Immunol 2008; 152: 153-162.
78. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008, e-pub ahead of print.
79. Stagg J, Pommey S, Eliopoulos N, Galipeau J. Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 2006; 107: 2570-2577.
80. Nauta AJ, Fibbe WE. Immunomodulatory properties of mesenchymal stromal cells. Blood 2007; 110: 3499-3506.
81. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371: 1579-1586.
82. Wolf D, Wolf AM. Mesenchymal stem cells as cellular immunosuppressants. Lancet 2008; 371: 1553-1554.
83. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol 1994; 12: 991-1045.
84. Krampera M, Glennie S, Dyson J, Scott D, Laylor R, Simpson E et al. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003; 101: 3722-3729.
85. Ramasamy R, Tong CK, Seow HF, Vidyadaran S, Dazzi F. The immunosuppressive effects of human bone marrow-derived mesenchymal stem cells target T cell proliferation but not its effector function. Cell Immunol 2008; 251: 131-136.
86. Bocelli-Tyndall C, Bracci L, Schaeren S, Feder-Mengus C, Barbero A, Tyndall A et al. Human bone marrow mesenchymal stem cells and chondrocytes promote and/or suppress the in vitro proliferation of lymphocytes stimulated with the cytokines IL 2, IL 7 and IL 15. Ann Rheum Dis 2008, e-pub ahead of print.
87. Kiel MJ, Yilmaz OH, Iwashita T, Yilmaz OH, Terhorst C, Morrison SJ. SLAM family receptors distinguish hematopoietic stem and progenitor cells and reveal endothelial niches for stem cells. Cell 2005; 121: 1109-1121.
88. Bryder D, Rossi DJ, Weissman IL. Hematopoietic stem cells: the paradigmatic tissue-specific stem cell. Am J Pathol 2006; 169: 338-346.
89. Calvi LM, Adams GB, Weibrecht KW, Weber JM, Olson DP, Knight MC et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 2003; 425: 841-846.
90. Zhang J, Niu C, Ye L, Huang H, He X, Tong WG et al. Identification of the haematopoietic stem cell niche and control of the niche size. Nature 2003; 425: 836-841.
91. Sacchetti B, Funari A, Michienzi S, Di Cesare S, Piersanti S, Saggio I et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 2007; 131: 324-336.
92. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity 2006; 25: 977-988.
93. Kiel MJ, Morrison SJ. Uncertainty in the niches that maintain haematopoietic stem cells. Nat Rev Immunol 2008; 8: 290-301.
94. Fossiez F, Djossou O, Chomarat P, Flores-Romo L, Ait-Yahia S, Maat C et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996; 183: 2593-2603.
95. Ley K, Smith E, Stark MA. IL-17A-producing neutrophil-regulatory Tn lymphocytes. Immunol Res 2006; 34: 229-242.
96. Treacy M, Lai L, Costello C, Clark A. Peripheral blood and bone marrow abnormalities in patients with HIV related disease. Br J Haematol 1987; 65: 289-294.
97. Laakko T, Fraker P. Rapid changes in the lymphopoietic and granulopoietic compartments of the marrow caused by stress levels of corticosterone. Immunology 2002; 105: 111-119.
98. Trottier MD, Newsted MM, King LE, Fraker PJ. Natural glucocorticoids induce expansion of all developmental stages of murine bone marrow granulocytes without inhibiting function. Proc Natl Acad Sci USA 2008; 105: 2028-2033.
99. Calignano A, Carnuccio R, Di Rosa M, Ialenti A, Moncada S. The anti-inflammatory effect of glucocorticoid-induced phospholipase inhibitory proteins. Agents Actions 1985; 16: 60-62.
100. Moorhead JW, Claman HN. Thymus-derived lymphocytes and hydrocortisone: identification of subsets of theta-bearing cells and redistribution to bone marrow. Cell Immunol 1972; 5: 74-86.
101. Fauci AS. Mechanisms of corticosteroid action on lymphocyte subpopulations. I. Redistribution of circulating T and B lymphocytes to the bone marrow. Immunology 1975; 28: 669-680.
102. Stefanski V, Peschel A, Reber S. Social stress affects migration of blood T cells into lymphoid organs. J Neuroimmunol 2003; 138: 17-24.
103. Ghosh MC, Baatar D, Collins G, Carter A, Indig F, Biragyn A et al. Dexamethasone augments CXCR4-mediated signaling in resting human T cells via the activation of the Src kinase Lck. Blood 2008, e-pub ahead of print.
104. Levine MA, Claman HN. Bone marrow and spleen: dissociation of immunologic properties by cortisone. Science 1970; 167: 1515-1517.
105. Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med 1998; 188: 997-1001.
106. Josien R, Wong BR, Li HL, Steinman RM, Choi Y. TRANCE, a TNF family member, is differentially expressed on T cell subsets and induces cytokine production in dendritic cells. J Immunol 1999; 162: 2562-2568.
107. Yun TJ, Tallquist MD, Aicher A, Rafferty KL, Marshall AJ, Moon JJ et al. Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. J Immunol 2001; 166: 1482-1491.
108. Choi Y, Woo KM, Ko SH, Lee YJ, Park SJ, Kim HM et al. Osteoclastogenesis is enhanced by activated B cells but suppressed by activated CD8(+) T cells. Eur J Immunol 2001; 31: 2179-2188.
109. Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999; 397: 315-323.
110. Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M et al. TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 2000; 191: 495-502.
111. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999; 103: 1345-1352.
112. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 1999; 402: 304-309.
113. Teng YT, Nguyen H, Gao X, Kong YY, Gorczynski RM, Singh B et al. Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. J Clin Invest 2000; 106: R59-R67.
114. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev 2008; 223: 87-113.
115. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002; 100: 4615-4621.
116. Giuliani N, Morandi F, Tagliaferri S, Colla S, Bonomini S, Sammarelli G et al. Interleukin-3 (IL-3) is overexpressed by T lymphocytes in multiple myeloma patients.[letter]. Blood 2006; 107: 841-842.
117. Blair JM, Zhou H, Seibel MJ, Dunstan CR. Mechanisms of disease: roles of OPG, RANKL and RANK in the pathophysiology of skeletal metastasis. Nat Clin Pract Oncol 2006; 3: 41-49.
118. Roggia C, Gao Y, Cenci S, Weitzmann MN, Toraldo G, Isaia G et al. Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci USA 2001; 98: 13960-13965.
119. Pacifici R. T cells and post menopausal osteoporosis in murine models. Arthritis Res Ther 2007; 9: 102.
120. D'Amelio P, Grimaldi A, Di Bella S, Brianza SZ, Cristofaro MA, Tamone C et al. Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone 2008; 43: 92-100.
121. + T lymphocytes in osteoclast differentiation in vitro. Endocrinology 1996; 137: 2457-2463.
122. Grcevic D, Lee SK, Marusic A, Lorenzo JA. Depletion of CD4 and CD8 T lymphocytes in mice in vivo enhances 1,25-dihydroxyvitamin D3-stimulated osteoclast-like cell formation in vitro by a mechanism that is dependent on prostaglandin synthesis. J Immunol 2000; 165: 4231-4238.
123. Appelbaum FR. The current status of hematopoietic cell transplantation. Annu Rev Med 2003; 54: 491-512.
124. Symons HJ, Fuchs EJ. Hematopoietic SCT from partially HLA-mismatched (HLA-haploidentical) related donors. Bone Marrow Transplant 2008; 42: 365-377.
125. Mirmonsef P, Tan G, Zhou G, Morino T, Noonan K, Borrello I et al. Escape from suppression: tumor-specific effector cells outcompete regulatory T cells following stem-cell transplantation. Blood 2008; 111: 2112-2121.
126. Serafini P, Borrello I, Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 2006; 16: 53-65.
127. Vasconcelos ZF, Dos Santos BM, Farache J, Palmeira TS, Areal RB, Cunha JM et al. G-CSF-treated granulocytes inhibit acute graft-versus-host disease. Blood 2006; 107: 2192-2199.
128. Gazitt Y. Immunologic profiles of effector cells and peripheral blood stem cells mobilized with different hematopoietic growth factors. Stem Cells 2000; 18: 390-398.
129. Carrasco J, Godelaine D, Van Pel A, Boon T, van der Bruggen P. CD45RA on human CD8 T cells is sensitive to the time elapsed since the last antigenic stimulation. Blood 2006; 108: 2897-2905.
130. Perez-Simon JA, Sureda A, Fernandez-Aviles F, Sampol A, Cabrera JR, Caballero D et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients [letter]. Leukemia 2006; 20: 542-545.